FTC Sues Hims & Hers for Sharing Health Data with Meta and Snap
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
FTC, Utah and California sue Hims & Hers for sharing users’ health data with Meta and Snap despite privacy promises, plus deceptive billing.
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
FDA advisers voted 8-6 to let compounding pharmacies make the popular peptide BPC-157 with a prescription. Not full approval.
Hims & Hers offers cheaper generic semaglutide in Canada ($149/mo) with medical support for weight loss care.
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.
JPMorgan backs Hims & Hers Health as a strong buy, boosted by GLP-1 drugs and big deals with Novo Nordisk and Eli Lilly.